Sinil Pharmaceutical Co. Ltd (012790) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinil Pharmaceutical Co. Ltd (012790) has a cash flow conversion efficiency ratio of 0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.62 Billion ≈ $1.78 Million USD) by net assets (₩151.71 Billion ≈ $102.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sinil Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Sinil Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Sinil Pharmaceutical Co. Ltd (012790) total liabilities for a breakdown of total debt and financial obligations.
Sinil Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinil Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aether Holdings, Inc.
NASDAQ:ATHR
|
-0.299x |
|
PetMed Express Inc
NASDAQ:PETS
|
-0.281x |
|
Samebest Co Ltd
TWO:8489
|
-0.017x |
|
Fonet Bilgi Teknolojileri AS
IS:FONET
|
0.102x |
|
Ege Seramik Sanayi ve Ticaret AS
IS:EGSER
|
-0.103x |
|
Mildex Optical
TWO:4729
|
0.002x |
|
Bowler Metcalf Ltd
JSE:BCF
|
0.092x |
|
Ymc Co. Ltd
KQ:155650
|
0.014x |
Annual Cash Flow Conversion Efficiency for Sinil Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Sinil Pharmaceutical Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Sinil Pharmaceutical Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩146.51 Billion ≈ $99.28 Million |
₩22.69 Billion ≈ $15.38 Million |
0.155x | +37.85% |
| 2023-12-31 | ₩134.90 Billion ≈ $91.42 Million |
₩15.15 Billion ≈ $10.27 Million |
0.112x | +1.18% |
| 2022-12-31 | ₩123.28 Billion ≈ $83.54 Million |
₩13.69 Billion ≈ $9.28 Million |
0.111x | +12.59% |
| 2021-12-31 | ₩113.20 Billion ≈ $76.71 Million |
₩11.16 Billion ≈ $7.57 Million |
0.099x | -4.18% |
| 2020-12-31 | ₩107.48 Billion ≈ $72.84 Million |
₩11.06 Billion ≈ $7.50 Million |
0.103x | -15.33% |
| 2019-12-31 | ₩101.24 Billion ≈ $68.61 Million |
₩12.31 Billion ≈ $8.34 Million |
0.122x | +25.83% |
| 2018-12-31 | ₩95.18 Billion ≈ $64.51 Million |
₩9.19 Billion ≈ $6.23 Million |
0.097x | +1.27% |
| 2017-12-31 | ₩90.93 Billion ≈ $61.62 Million |
₩8.67 Billion ≈ $5.88 Million |
0.095x | -31.23% |
| 2016-12-31 | ₩87.19 Billion ≈ $59.09 Million |
₩12.09 Billion ≈ $8.20 Million |
0.139x | +13.38% |
| 2015-12-31 | ₩78.17 Billion ≈ $52.98 Million |
₩9.56 Billion ≈ $6.48 Million |
0.122x | -7.08% |
| 2014-12-31 | ₩70.85 Billion ≈ $48.01 Million |
₩9.33 Billion ≈ $6.32 Million |
0.132x | -- |
About Sinil Pharmaceutical Co. Ltd
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, incl… Read more